CNR Institutional Research Information System

PIZZINI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.847
NA - Nord America 1.600
EU - Europa 565
SA - Sud America 440
Continente sconosciuto - Info sul continente non disponibili 103
AF - Africa 46
OC - Oceania 6
Totale 4.607
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.491
SG - Singapore 833
CN - Cina 367
BR - Brasile 338
IT - Italia 230
HK - Hong Kong 195
VN - Vietnam 190
FR - Francia 128
BD - Bangladesh 64
CA - Canada 54
KR - Corea 47
GB - Regno Unito 38
IN - India 36
DE - Germania 30
NL - Olanda 29
AR - Argentina 24
FI - Finlandia 23
CO - Colombia 19
JP - Giappone 18
EC - Ecuador 17
ID - Indonesia 16
VE - Venezuela 13
RU - Federazione Russa 12
JM - Giamaica 11
PE - Perù 11
IE - Irlanda 10
PL - Polonia 10
TR - Turchia 10
MX - Messico 9
ZA - Sudafrica 9
CR - Costa Rica 8
ES - Italia 8
PH - Filippine 8
IQ - Iraq 7
MA - Marocco 7
SA - Arabia Saudita 7
UY - Uruguay 7
AT - Austria 6
IL - Israele 6
MY - Malesia 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
HN - Honduras 5
HR - Croazia 5
KE - Kenya 5
PK - Pakistan 5
SE - Svezia 5
UA - Ucraina 5
AU - Australia 4
BO - Bolivia 4
CL - Cile 4
NI - Nicaragua 4
NP - Nepal 4
AL - Albania 3
AO - Angola 3
BB - Barbados 3
BE - Belgio 3
ET - Etiopia 3
GT - Guatemala 3
PY - Paraguay 3
TH - Thailandia 3
TN - Tunisia 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DZ - Algeria 2
GR - Grecia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
MT - Malta 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
RO - Romania 2
TW - Taiwan 2
AZ - Azerbaigian 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MR - Mauritania 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
Totale 4.497
Salva come PNG Salva come JPEG
Città #
Singapore 528
Santa Clara 283
Hong Kong 194
San Jose 138
Ashburn 105
Hefei 105
Council Bluffs 104
Lauterbourg 104
Ho Chi Minh City 74
Beijing 67
Los Angeles 52
Seoul 47
Hanoi 45
New York 36
Dallas 33
São Paulo 27
Princeton 25
Milan 20
Buffalo 17
Abbeville 14
Frankfurt am Main 14
Rome 12
Toronto 12
Rio de Janeiro 11
Chicago 10
Helsinki 10
Tokyo 10
Brooklyn 9
Curitiba 9
Dublin 9
Brasília 8
Düsseldorf 8
Miami 8
Montreal 8
Warsaw 8
Amsterdam 7
Biên Hòa 7
Da Nang 7
Lappeenranta 7
Orem 7
The Bronx 7
Atlanta 6
Baghdad 6
Belo Horizonte 6
Bologna 6
Dhaka 6
Guayaquil 6
Haiphong 6
Lima 6
Louisville 6
Naples 6
Philadelphia 6
Quito 6
San José 6
Tampa 6
Turku 6
Washington 6
Austin 5
Bari 5
Bengaluru 5
Boston 5
Catania 5
Chennai 5
Denver 5
Florence 5
Kingston 5
Las Vegas 5
London 5
Minamishinagawa 5
New Orleans 5
Newark 5
Phoenix 5
Queens 5
Salvador 5
Zagreb 5
Belém 4
Cleveland 4
Ha Long 4
Houston 4
Hải Dương 4
Jakarta 4
Johannesburg 4
Joinville 4
McAllen 4
Medellín 4
Mumbai 4
New Delhi 4
Paris 4
Paternò 4
Sheffield 4
Stockholm 4
Turin 4
Vienna 4
Addis Ababa 3
Barquisimeto 3
Bogotá 3
Bridgetown 3
Cairo 3
Cali 3
Cape Town 3
Totale 2.485
Salva come PNG Salva come JPEG
Nome #
Role of Gut Microbiota in Overweight Susceptibility in an Adult Population in Italy 138
8-hydroxy-2′-deoxyguanosine, a biomarker of oxidative DNA injury, in diabetic kidney disease 132
Osteopontin, death and cardiovascular events in stage G3–4 CKD patients: a joint model analysis 95
Socioeconomic Status and Clinical Outcomes in Chronic Kidney Disease: Bootstrap Validation of a Simple Indicator 90
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients 89
Osteopontin and Clinical Outcomes in Hemodialysis Patients 80
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Acute Kidney Injury in Patients Undergoing Cardiopulmonary Bypass 80
Il peptide natriuretico (BNP) è un biomarcatore della congestione polmonare nei pazienti in dialisi. 79
Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients 74
Plasma levels of myeloperoxidase and resistin independently predict mortality in dialysis patients 74
Inflammation biomarkers and inflammatory genes expression in metabolically healthy obese patients 73
Quality of life and kidney function in CKD patients: a longitudinal study 71
Selenoprotein P-1 (SEPP1) as an Early Biomarker of Myocardial Injury in Patients Undergoing Cardiopulmonary Bypass 71
Reducing salt intake by urine chloride self-measurement in non-compliant patients with chronic kidney disease followed in nephrology clinics: a randomized trial 69
Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension 68
Perioperative Marinobufagenin (MBG) Measurement May Improve Acute Kidney Injury Risk Assessment in Patients Undergoing Major Cardiac Surgery: A Proof-of-Concept Study 68
CKD-MBD biomarkers and CKD progression: an analysis by the joint model 64
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study 59
Salt intake correlates with night systolic blood pressure in non-dialytic chronic kidney disease 59
Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity 58
Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD 58
FGF23 and the PTH response to paricalcitol in chronic kidney disease 57
Intact FGF23 and ?-klotho during acute inflammation/sepsis in CKD patients 54
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 52
Procalcitonin and the inflammatory response to salt in essential hypertension: A randomized cross-over clinical trial 52
Neuropeptide Y and chronic kidney disease progression: a cohort study 52
Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients. 49
Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients 49
Resistin and all-cause and cardiovascular mortality: Effect modification by adiponectin in end-stage kidney disease patients 49
Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial 48
Intact FGF23 and -klotho during acute inflammation/sepsis in CKD patients 47
Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients 47
Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial 46
Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. 45
INDICES OF INSULIN RESISTANCE AND RISK OF TOTAL AND CARDIOVASCULAR MORTALITY IN DIALYSIS PATIENTS 44
L'obesità addominale interagisce con due citochine prodotte dal tessuto adiposo, Leptina ed Adiponectina, per predire il rischio di mortalità totale e cardiovascolare nei pazienti in dialisi. 44
Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients 44
Long term predictors of cerebrovascular events in patients with end stage renal disease (ESRD). 43
I polimorfismi del gene ENPP1 si associano ad ipertrofia ventricolare sinistra ed alla funzione sistolica nei pazienti in dialisi. 43
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD) 42
Vitamin D and methylarginines in chronic kidney disease (CKD) 42
Smoking and hyperparathyroidism in patients with end-stage renal disease (ESRD). 40
C-Reactive Protein and Interleukin-6 modify the risk of high levels of Asymmetric Dimethyl-Arginine (ADMA) for death and cardiovascular events in end stage renal diseases patients. 39
Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study. 39
Vitamin D receptor activation by paricalcitol and insulin resistance in CKD 39
Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. 37
Leptin and biochemical markers of bone turnover in dialysis patients 36
Il rischio di progressione delle nefropatie croniche e mortalità: ruolo dell'Asymmetrical Di-Methil-Arginine (ADMA). 35
Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial 35
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in ckd patients. 35
Association between resistin levels and all-cause and cardiovascular mortality: A new study and a systematic review and meta-analysis 35
Low triiodothyronine and survival in end stage renal disease (ESRD). 35
Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels 35
Urotensin II and cardiomyopathy in end-stage renal disease. 34
FGF23 beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease patients. 34
Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. 34
Low triiodothyronine and survival in end-stage renal disease. 33
Inflammation downregulates FGF23 in chronic kidney disease (CKD) patients. 33
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease 33
Pattern evolutivo dei biomarcatori di infiammazione e dei fattori di rischio non tradizionali dopo trapianto renale. 32
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end stage renal disease (ESRD). 32
Urotensin II is inversely related to markers of endothelial activation and inflammation and is an inverse predictor of incident cardiovascolar events in end stage renal disease (ESRD). 31
Vascular Endothelial Growth Factor, rimodellamento ventricolare sinistro e disfunzione sistolica nei pazienti in dialisi 31
L'infiammazione amplifica il rischio di mortalità ed eventi cardiovascolari connesso ai livelli circolanti di dimetilarginina asimmetrica (ADMA) nei pazienti in dialisi. 31
Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease 30
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 30
Vascular endothelial growth factor (VRGF) is a marker of left ventricular dysfunction and predicts mortality in hemodialysis (HD) patients. 30
Asymmetric Dimethylarginine (ADMA) Enzymatic Machinery and Adipokines Gene Expression in the Adipose Tissue in Stage 3-5 CKD patients. 30
Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients 30
Waist circumference modifies the relationship of adipose tissue cytochines leptin and adiponectin with all-cause and cardiovascular mortality in end stage renal disease (ESRD). 30
Vitamin D levels and patient outcome in chronic kidney disease. 29
Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcome stage renal disease patients. 29
Insulin Sensitivity, Systemic Inflammation and Adipose Tissue Gene Expression of Inflammatory Cytokines in Chronic Kidney Disease (CKD) and in Obese Patients. 29
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 29
Low Triiodothyronine and Cardiomyopathy in Patients with End-Stage Renal Disease (ESRD). 28
Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease 28
L'iperparatiroidismo e il TNF-a come determinanti dell'incidenza di fratture nei pazienti in dialisi: uno studio di coorte. 28
Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides 28
Methylarginine enzymatic machinery and Leptin in adipose tissue in CKD patients. 28
Urotensin II partecipates in cardiovascular control in end stage renal disease (ESRD). 27
Beyond bone mineral metabolism: functional relationship with inflammation in chronic kidney disease (CKD) patients. 27
Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. 27
Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. 26
Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study 26
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). 26
Functional correlates and gene expression in fat cells of visfatin/pre-b cell enhancing factor in CKD patients. 26
Circulating soluble RAGE in patients with chronic kidney disease as an inverse correlate of atherosclerosis. 26
I predittori degli eventi cardiovascolari nei pazienti in dialisi. 26
Methylarginine enzymatic machinery and Leptin in adipose tissue in CKD patients. 25
L'ipotiroidismo subclinico si associa alla micro-infiammazione cronica e predice la mortalità nei pazienti in CAPD. Risultati di uno studio pilota di coorte. 25
Low triiodothyronine: a new facet of inflammation in end-stage renal disease. 25
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. 24
Smoking and hyperparathyroidism in patients with end stage renal disease (ESRD). 24
Valore diagnostico per il basso turnover osseo del PTH dosato con metodi RIA di prima e seconda generazione. 24
Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections 24
Intact FGF23 and -klotho during acute inflammation/sepsis in CKD patients 23
BRAIN NATRIURETIC PEPTIDE AS A BIOMARKER OF PULMONARY CONGESTION IN STAGE 5 CKD ON DIALYSIS 23
Vascular endothelial growth factor, left ventricular remodeling and systolic dysfunction in end stage renal disease 23
Which is the best inflammation marker? A comparative study based on multivariate modelling of mortality in end stage renal disease (ESRD) patients. 22
Low Triiodothyronine (fT3): a new facet of inflammation in end stage renale disease (ESRD). 22
Totale 4.353
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.411
article - articoli 10.904
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.315
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202439 0 0 0 0 0 0 0 0 32 0 7 0
2024/20251.487 6 12 115 91 307 27 33 103 44 58 376 315
2025/20262.226 96 199 226 313 412 87 346 159 95 138 102 53
2026/2027855 203 110 288 254 0 0 0 0 0 0 0 0
Totale 4.607